albertsons diamond bar

Boosh Begins US Export With 16,000 Units

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is pleased to announce it has begun its US expansion with the first shipment of 16,000 units to its US distribution warehouse. The shipment includes an equal portion of our six frozen entrees; Shepard's Pie with Beyond Meat™, Rustic Pot Pie, Mexican Fiesta Bowl, Coconut Curry Cali, Mac & Cheeze & Peas and Veggie Bolognese with Beyond Meat™.

"As we have begun to send samples to our US food broker to distribute to key accounts in the US the feedback has been extremely positive. In fact, our first shipment to the US distribution center was anticipated to be 10,000 units, however, because of the high interest, we've increased it to 16,000 units," states founder and president Connie Marples.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7944/101127_bfac408fe451fbde_002.jpg

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7944/101127_bfac408fe451fbde_002full.jpg

After an extended search, Boosh is proud to announce the hiring of TJ Walsh as VP of Sales for North America. Boosh's recently formed sales department will be reporting to TJ, who will be responsible for all sales strategy, development, direction and budget. TJ will be developing on-site sales training and policy formulation, and will report directly to the president, Connie Marples, and CEO Jim Pakulis. He has extensive sales experience including, but not limited, to National Director of Sales for Silver Hills, a plant-based bakery and organic foods company. Prior to that he was Sales Manager for UNFI, North America's largest all natural and organic distributor. Previously he spent eight years with Bolthouse Farms eventually being promoted to Director of Field Sales. At Bolthouse Farms he was responsible for implementing a multi-million dollar sales budget, overseeing 30 sales representatives, developing strategic growth plans for selling all new product lines, and creating merchandising and sales strategies for Walmart, Kroger, Target, Safeway/Albertsons, HEB, Loblaws, Save On, Kroger's and Whole Foods.

"The timing of our first shipment to the US is aligning perfectly with the hiring of TJ. As we've grown the SKU count from 6 at the beginning of the year to 24 SKU's today, we'll be needing to expand our North American sales department, and we believe TJ is the perfect candidate for the undertaking. And the fact he grew up in the US and now resides in Vancouver is another major advantage for Boosh," states CEO Jim Pakulis.

"I have over fourteen years of either selling or overseeing sales teams in the natural food industry, both in the US and Canada. With my comprehensive knowledge and deep relationships with grocery store buyers, I believe I'll be a strong asset and will provide sales leadership as we continue to expand our retail footprint throughout North America," states TJ Walsh.

In other news, the Company retained the services of Globull Media LLC to provide investment relations services. The provider is charging the Company US fifty thousand dollars for one month of service.

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer
Telephone: (833) 882-6674
www.Booshfood.com

Investor Relations
Contact - Edge Communications Group
Email: invest@booshfood.com
Telephone: (236) 237-1315

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals and three refrigerated meals which are sold throughout Canada. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101127

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News

×